Literature DB >> 20396984

Tailored community cancer education programs: Pawsox and prostates.

Arvin S Glicksman1, Andrea Meyer, Maureen Dipiero.   

Abstract

To assess the prostate cancer screening practices in Rhode Island, we designed a questionnaire which was sent to 150 primary care physicians. A population-based survey was distributed to 194 men over 40 asking about screening history and risk factors. Eighty-five percent of primary care physicians reported performing annual prostate-specific antigen tests (PSAs) and digital rectal exams, 63% recognized family history as a risk factor, and 14% identified African Americans as a high-risk population. The survey found that 48% of men recognized family history as a risk factor and 6% understood that African Americans were at high risk. Each year, 200 men, primarily SED, are invited to a PawSox baseball game where physicians provide information on prostate cancer risk, treatment options, and outcomes. Free PSAs are provided. The questionnaire and survey demonstrate a need for more public education regarding prostate cancer in high-risk populations. Tailored community-based interventions, such as the Pawsox & Prostate program, can be effective professional and public education strategies to increase screening in high-risk populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20396984     DOI: 10.1007/s13187-009-0029-6

Source DB:  PubMed          Journal:  J Cancer Educ        ISSN: 0885-8195            Impact factor:   2.037


  2 in total

1.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

2.  Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort.

Authors:  Xianglin L Du; Shenying Fang; Ann L Coker; Maureen Sanderson; Corrine Aragaki; Janice N Cormier; Yan Xing; Beverly J Gor; Wenyaw Chan
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.